Open tender · Czechia · Antineoplastic agents
Perorální Cytostatikum s obsahovou látkou Belzutifanum
In EnglishOral Cytostatic with active substance Belzutifanum
Fakultní nemocnice Ostrava in Czechia is inviting bids for “Oral Cytostatic with active substance Belzutifanum”. Bids close on 13 October 2026, 12:00 CEST; the estimated value is CZK 50.25 million. askTender lists every requirement to qualify and checks whether your company meets them.
The tender in brief
Repeated deliveries of the oral cancer medicine Belzutifanum 40 mg to a Czech hospital
The contract covers ongoing, repeated deliveries of the oral cancer medicine Belzutifanum, 40 mg in one coated tablet, to the contracting authorities. Deliveries are made against individual orders. The contract is awarded on the lowest total bid price excluding VAT.
Key facts
- Estimated value
- CZK 50.25 million
- Procedure
- Contract notice
- How bids are judged
- Lowest total bid price excluding VAT
Before you bid, askTender
Everything else is in your askTender account
The requirements to qualify, the eligibility check and the bid documents for this tender are in your askTender account.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences